Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

A risk-based approach to reducing exposure of staff to laboratory animal allergens.

Westall L, Graham IR, Bussell J.

Lab Anim (NY). 2015 Jan;44(1):32-8. doi: 10.1038/laban.603. Review.

PMID:
25526057
2.

Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.

Popplewell LJ, Graham IR, Malerba A, Dickson G.

Methods Mol Biol. 2011;709:153-78. doi: 10.1007/978-1-61737-982-6_10.

PMID:
21194027
3.

Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice.

Malerba A, Sharp PS, Graham IR, Arechavala-Gomeza V, Foster K, Muntoni F, Wells DJ, Dickson G.

Mol Ther. 2011 Feb;19(2):345-54. doi: 10.1038/mt.2010.261. Epub 2010 Nov 23.

4.

Adeno-associated virus serotypes 7 and 8 outperform serotype 9 in expressing atheroprotective human apoE3 from mouse skeletal muscle.

Evans VC, Graham IR, Athanasopoulos T, Galley DJ, Jackson CL, Simons JP, Dickson G, Owen JS.

Metabolism. 2011 Apr;60(4):491-8. doi: 10.1016/j.metabol.2010.04.015. Epub 2010 May 23.

PMID:
20580777
5.

Transcriptomic analysis of dystrophin RNAi knockdown reveals a central role for dystrophin in muscle differentiation and contractile apparatus organization.

Ghahramani Seno MM, Trollet C, Athanasopoulos T, Graham IR, Hu P, Dickson G.

BMC Genomics. 2010 Jun 1;11:345. doi: 10.1186/1471-2164-11-345.

6.

Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials.

Popplewell LJ, Adkin C, Arechavala-Gomeza V, Aartsma-Rus A, de Winter CL, Wilton SD, Morgan JE, Muntoni F, Graham IR, Dickson G.

Neuromuscul Disord. 2010 Feb;20(2):102-10. doi: 10.1016/j.nmd.2009.10.013. Epub 2010 Jan 15.

PMID:
20079639
7.

Efficient liver-directed gene transfer by in situ generation of retroviral vector from adenoviral templates.

Harris JD, Roberts ML, Perumal D, Graham IR, Patterson S, Dickson G.

In Vivo. 2009 Nov-Dec;23(6):885-93.

8.

Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.

Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, Guglieri M, Ashton E, Abbs S, Nihoyannopoulos P, Garralda ME, Rutherford M, McCulley C, Popplewell L, Graham IR, Dickson G, Wood MJ, Wells DJ, Wilton SD, Kole R, Straub V, Bushby K, Sewry C, Morgan JE, Muntoni F.

Lancet Neurol. 2009 Oct;8(10):918-28. doi: 10.1016/S1474-4422(09)70211-X. Epub 2009 Aug 25. Erratum in: Lancet Neurol. 2009 Dec;8(12):1083.

9.

Dosing regimen has a significant impact on the efficiency of morpholino oligomer-induced exon skipping in mdx mice.

Malerba A, Thorogood FC, Dickson G, Graham IR.

Hum Gene Ther. 2009 Sep;20(9):955-65. doi: 10.1089/hum.2008.157.

PMID:
19469709
10.

Adeno-associated virus-8-mediated intravenous transfer of myostatin propeptide leads to systemic functional improvements of slow but not fast muscle.

Foster K, Graham IR, Otto A, Foster H, Trollet C, Yaworsky PJ, Walsh FS, Bickham D, Curtin NA, Kawar SL, Patel K, Dickson G.

Rejuvenation Res. 2009 Apr;12(2):85-94. doi: 10.1089/rej.2008.0815.

PMID:
19405813
11.

Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene.

Popplewell LJ, Trollet C, Dickson G, Graham IR.

Mol Ther. 2009 Mar;17(3):554-61. doi: 10.1038/mt.2008.287. Epub 2009 Jan 13.

12.

Preliminary evaluation of a self-complementary AAV2/8 vector for hepatic gene transfer of human apoE3 to inhibit atherosclerotic lesion development in apoE-deficient mice.

Osman E, Evans V, Graham IR, Athanasopoulos T, McIntosh J, Nathwani AC, Simons JP, Dickson G, Owen JS.

Atherosclerosis. 2009 May;204(1):121-6. doi: 10.1016/j.atherosclerosis.2008.08.043. Epub 2008 Sep 11.

PMID:
18930458
13.

Adenovirus-based targeting in myoblasts is hampered by nonhomologous vector integration.

Isman O, Roberts ML, Morgan JE, Graham IR, Goldring K, Lawrence-Watt DJ, Lu QL, Dunckley MG, Porter AC, Partridge TA, Dickson G.

Hum Gene Ther. 2008 Oct;19(10):1000-8. doi: 10.1089/hum.2008.063.

PMID:
18788904
14.

Codon and mRNA sequence optimization of microdystrophin transgenes improves expression and physiological outcome in dystrophic mdx mice following AAV2/8 gene transfer.

Foster H, Sharp PS, Athanasopoulos T, Trollet C, Graham IR, Foster K, Wells DJ, Dickson G.

Mol Ther. 2008 Nov;16(11):1825-32. doi: 10.1038/mt.2008.186. Epub 2008 Sep 2.

15.

Human apolipoprotein E expression from mouse skeletal muscle by electrotransfer of nonviral DNA (plasmid) and pseudotyped recombinant adeno-associated virus (AAV2/7).

Evans V, Foster H, Graham IR, Foster K, Athanasopoulos T, Simons JP, Dickson G, Owen JS.

Hum Gene Ther. 2008 Jun;19(6):569-78. doi: 10.1089/hum.2007.169.

PMID:
18578629
16.

RNAi-mediated knockdown of dystrophin expression in adult mice does not lead to overt muscular dystrophy pathology.

Ghahramani Seno MM, Graham IR, Athanasopoulos T, Trollet C, Pohlschmidt M, Crompton MR, Dickson G.

Hum Mol Genet. 2008 Sep 1;17(17):2622-32. doi: 10.1093/hmg/ddn162. Epub 2008 May 28.

PMID:
18511456
17.

Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle.

Arechavala-Gomeza V, Graham IR, Popplewell LJ, Adams AM, Aartsma-Rus A, Kinali M, Morgan JE, van Deutekom JC, Wilton SD, Dickson G, Muntoni F.

Hum Gene Ther. 2007 Sep;18(9):798-810.

PMID:
17767400
18.

Apolipoprotein E delivery by peritoneal implantation of encapsulated recombinant cells improves the hyperlipidaemic profile in apoE-deficient mice.

Tagalakis AD, Diakonov IA, Graham IR, Heald KA, Harris JD, Mulcahy JV, Dickson G, Owen JS.

Biochim Biophys Acta. 2005 Jan 5;1686(3):190-9.

PMID:
15629688
19.

Recombinant adeno-associated viral (rAAV) vectors as therapeutic tools for Duchenne muscular dystrophy (DMD).

Athanasopoulos T, Graham IR, Foster H, Dickson G.

Gene Ther. 2004 Oct;11 Suppl 1:S109-21. Review.

PMID:
15454965
21.

Screening for antisense modulation of dystrophin pre-mRNA splicing.

Dickson G, Hill V, Graham IR.

Neuromuscul Disord. 2002 Oct;12 Suppl 1:S67-70. Review.

PMID:
12206799
22.

Stable micro-dystrophin gene transfer using an integrating adeno-retroviral hybrid vector ameliorates the dystrophic pathology in mdx mouse muscle.

Roberts ML, Wells DJ, Graham IR, Fabb SA, Hill VJ, Duisit G, Yuasa K, Takeda S, Cosset FL, Dickson G.

Hum Mol Genet. 2002 Jul 15;11(15):1719-30.

PMID:
12095914
24.

Inhibition of atherosclerosis in apolipoprotein-E-deficient mice following muscle transduction with adeno-associated virus vectors encoding human apolipoprotein-E.

Harris JD, Schepelmann S, Athanasopoulos T, Graham IR, Stannard AK, Mohri Z, Hill V, Hassall DG, Owen JS, Dickson G.

Gene Ther. 2002 Jan;9(1):21-9.

25.

Acute regression of advanced and retardation of early aortic atheroma in immunocompetent apolipoprotein-E (apoE) deficient mice by administration of a second generation [E1(-), E3(-), polymerase(-)] adenovirus vector expressing human apoE.

Harris JD, Graham IR, Schepelmann S, Stannard AK, Roberts ML, Hodges BL, Hill V, Amalfitano A, Hassall DG, Owen JS, Dickson G.

Hum Mol Genet. 2002 Jan 1;11(1):43-58.

PMID:
11772998
26.

Oligonucleotide-based gene correction strategies: applications to neuromuscular and cardiovascular diseases.

Graham IR, Beattie SG, Hill VJ, Dickson G.

Croat Med J. 2001 Aug;42(4):467-72.

27.

Gene repair validation.

Graham IR, Manzano A, Tagalakis AD, Mohri Z, Sperber G, Hill V, Beattie S, Schepelmann S, Dickson G, Owen JS.

Nat Biotechnol. 2001 Jun;19(6):507-8. No abstract available.

PMID:
11385435
28.

Gene correction of the apolipoprotein (Apo) E2 phenotype to wild-type ApoE3 by in situ chimeraplasty.

Tagalakis AD, Graham IR, Riddell DR, Dickson JG, Owen JS.

J Biol Chem. 2001 Apr 20;276(16):13226-30. Epub 2001 Feb 13.

29.

In vivo analysis of functional regions within yeast Rap1p.

Graham IR, Haw RA, Spink KG, Halden KA, Chambers A.

Mol Cell Biol. 1999 Nov;19(11):7481-90.

30.

Prospective comparison of unenhanced spiral computed tomography and intravenous urogram in the evaluation of acute flank pain.

Miller OF, Rineer SK, Reichard SR, Buckley RG, Donovan MS, Graham IR, Goff WB, Kane CJ.

Urology. 1998 Dec;52(6):982-7. Review.

PMID:
9836541
31.

lambda Rap protein is a structure-specific endonuclease involved in phage recombination.

Sharples GJ, Corbett LM, Graham IR.

Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13507-12.

32.

Constitutive expression vectors: PGK.

Graham IR, Chambers A.

Methods Mol Biol. 1997;62:159-69. No abstract available.

PMID:
9108520
33.

Rap1p is a negative regulator of the RAP1 gene.

Graham IR, Chambers A.

Curr Genet. 1996 Jul 31;30(2):93-100.

PMID:
8660466
35.

Control of glycolytic gene expression in the budding yeast (Saccharomyces cerevisiae).

Chambers A, Packham EA, Graham IR.

Curr Genet. 1995 Dec;29(1):1-9. Review. No abstract available.

PMID:
8595651
37.
38.
39.

Mutually exclusive splicing of calcium-binding domain exons in chick alpha-actinin.

Waites GT, Graham IR, Jackson P, Millake DB, Patel B, Blanchard AD, Weller PA, Eperon IC, Critchley DR.

J Biol Chem. 1992 Mar 25;267(9):6263-71.

40.

Supplemental Content

Loading ...
Support Center